Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.89
- Piotroski Score 1.00
- Grade Buy
- Symbol (QURE)
- Company uniQure N.V.
- Price $5.66
- Changes Percentage (2.17%)
- Change $0.12
- Day Low $5.52
- Day High $5.79
- Year High $11.35
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $57.50
- High Stock Price Target $62.00
- Low Stock Price Target $34.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.20
- Trailing P/E Ratio -0.86
- Forward P/E Ratio -0.86
- P/E Growth -0.86
- Net Income $-308,478,000
Income Statement
Quarterly
Annual
Latest News of QURE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
uniQure N.V. reported bullish quarterly results with revenues beating estimates by 65%. Analysts expect a 66% revenue increase in 2024, despite a forecasted loss reduction. However, forecasts show a w...
By Yahoo! Finance | 1 month ago -
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
Institutional investors hold a majority stake in uniQure, impacting stock price. Hedge funds and CEO also own shares. Analysts recommend considering ownership structure alongside other factors for inv...
By Yahoo! Finance | 2 months ago
